Supplemental figures
Medical management of heavy menstrual bleeding: a comprehensive review
of the literature
Johannes Bitzer, MD, PhD,1 Oskari Heikinheimo, MD, PhD,2 Anita L. Nelson, MD,3 Joaquin Calaf-Alsina, MD, PhD,4 Ian S. Fraser, MD,
DSc5
1
Department of Obstetrics and Gynecology, University Hospital of Basel, Basel, Switzerland; 2Department of Obstetrics and Gynaecology,
Kätilöopisto Hospital, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 3Los Angeles BioMedical Research Institute
at Harbor-UCLA Medical Center, Torrance, CA USA; 4Department of Obstetrics and Gynaecology, Hospital de la Santa Creu i Sant Pau, Universitat
Autónoma, Barcelona, Spain; 5University of Sydney, Sydney, New South Wales, Australia
Corresponding author: Ian Fraser, Department of Obstetrics and Gynaecology, Central Clinical School, D02–QEII Research Institute for Mothers
and Infants, The University of Sydney, Sydney, NSW 2006, Australia. Phone: +61 2 9351 2478; Fax: +61 2 9351 4560; E-mail:
ian.fraser@sydney.edu.au
Supplemental Figure 1. Summary of the distribution of reported reductions in menstrual blood loss (MBL) in women with HMB due to endometrial
dysfunction (AUB-E) treated with the levonorgestrel-releasing intrauterine system (LNG-IUS): mean reductions reported by alkaline hematin (a) and
pictorial blood assessment chart scores [PBAC] (b), and median reductions reported by alkaline hematin (c) and PBAC scores (d). Each circle represents
data from a single study and the line represent the average trend at a given time point (1-27).
a)
b)
c)
d)
Supplemental Figure 2. Summary of the distribution of reported mean reductions in pictorial blood assessment chart scores [PBAC] in women HMB due
to endometrial dysfunction (AUB-E) (a) or leiomyomas (AUB-L) (b) treated with the levonorgestrel-releasing intrauterine system (LNG-IUS). Each circle
represents data from a single study and the line represent the average trend at a given time point (1, 4-6, 8, 9, 11-13, 15-17, 21, 23-25, 27-33).
a)
b)
Supplemental Figure 3. Summary of the distribution of reported mean reductions in menstrual blood loss (MBL) in women with HMB due to
endometrial dysfunction (AUB-E) following treatment with, a) the levonorgestrel-releasing intrauterine system (LNG-IUS), b) tranexamic acid
[includes data from Andersch et al 1988 where patients received tranexamic acid 1.5 mg TID on days 1 to 3 followed by 1 g BID for another two days
(34)], c) danazol, and d) non-steroidal anti-inflammatory drugs (NSAIDs). Each circle represents data from a single study and the line represent the
average trend at a given time point (3, 14, 16, 19, 20, 22, 34-46).
a)
b)
c)
d)
References
1.
Crosignani PG, Vercellini P, Mosconi P, et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the
treatment of dysfunctional uterine bleeding. Obstetrics and Gynecology 1997;90:257-63.
2.
Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and
norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology 1998;105:592-8.
3.
Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus
hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001;357:273-7.
4.
Soysal M, Soysal S, Ozer S. A randomized controlled trial of levonorgestrel releasing IUD and thermal balloon ablation in the treatment of
menorrhagia. Zentralblatt fur Gynakologie 2002;124:213-9.
5.
Barrington JW, Arunkalaivanan AS, Abdel-Fattah M. Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal
balloon ablation in the treatment of menorrhagia. European Journal of Obstetrics Gynecology and Reproductive Biology 2003;108:72-4.
6.
Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstetrics
and Gynecology 2004;104:1314-21.
7.
Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of
idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG : an
international journal of obstetrics and gynaecology 2005;112:1121-5.
8.
Abdel Malak K, Shawki O. Management of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection.
Gynecological Surgery 2006;3:275-80.
9.
Busfield RA, Farquhar CM, Sowter MC, et al. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon
ablation for heavy menstrual bleeding. BJOG: An International Journal of Obstetrics and Gynaecology 2006;113:257-63.
10.
Shaw RW, Symonds IM, Tamizian O, et al. Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in
patients with idiopathic menorrhagia. Australian and New Zealand Journal of Obstetrics and Gynaecology 2007;47:335-40.
11.
Kucuk T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the
treatment of perimenopausal menorrhagia: A randomized, prospective, controlled clinical trial in female smokers. Clinical and Experimental Obstetrics
and Gynecology 2008;35:57-60.
12.
Endrikat J, Shapiro H, Lukkari-Lax E, et al. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine
system to an oral contraceptive in women with idiopathic menorrhagia. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique
et gynecologie du Canada : JOGC 2009;31:340-7.
13.
de Souza SS, Camargos AF, de Rezende CP, et al. A randomized prospective trial comparing the levonorgestrel-releasing intrauterine system
with thermal balloon ablation for the treatment of heavy menstrual bleeding. Contraception 2010;81:226-31.
14.
Kaunitz AM, Bissonnette F, Monteiro I, et al. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual
bleeding: a randomized controlled trial. Obstetrics and gynecology 2010;116:625-32.
15.
Ghazizadeh S, Bakhtiari F, Rahmanpour H, et al. A randomized clinical trial to compare levonorgestrel-releasing intrauterine system (Mirena)
vs trans- ervical endometrial resection for treatment of menorrhagia. International Journal of Women's Health 2011;3:207-11.
16.
Shabaan MM, Zakherah MS, El-Nashar SA, et al. Levonorgestrel-releasing intrauterine system compared to low dose combined oral
contraceptive pills for idiopathic menorrhagia: A randomized clinical trial. Contraception 2011;83:48-54.
17.
Sesti F, Piancatelli R, Pietropolli A, et al. Levonorgestrel-releasing intrauterine system versus laparoscopic supracervical hysterectomy for the
treatment of heavy menstrual bleeding: a randomized study. J Womens Health (Larchmt) 2012;21:851-7.
18.
Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990;97:690-4.
19.
Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine
contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991;164:879-83.
20.
Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability.
Contraception 1995;51:231-5.
21.
Barrington JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol
1997;104:614-6.
22.
Xiao B, Wu SC, Chong J, et al. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic
menorrhagia. Fertil Steril 2003;79:963-9.
23.
Gupta B, Mittal S, Misra R, et al. Levonorgestrel-releasing intrauterine system vs. transcervical endometrial resection for dysfunctional uterine
bleeding. Int J Gynaecol Obstet 2006;95:261-6.
24.
Kriplani A, Singh BM, Lal S, et al. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J
Gynaecol Obstet 2007;97:190-4.
25.
Gorgen H, Api M, Akca A, et al. Use of the Levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users.
Arch Gynecol Obstet 2009;279:835-40.
26.
Chattopdhyay B, Nigam A, Goswami S, et al. Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagia. European
review for medical and pharmacological sciences 2011;15:764-8.
27.
Kriplani A, Awasthi D, Kulshrestha V, et al. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynaecol
Obstet 2012;116:35-8.
28.
Grigorieva V, Chen-Mok M, Tarasova M, et al. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine
leiomyomas. Fertil Steril 2003;79:1194-8.
29.
Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a
prospective controlled trial. Gynecol Obstet Invest 2005;59:29-35.
30.
Murat Naki M, Tekcan C, Ozcan N, et al. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia
among women of reproductive age without a significant regression in the uterine and leiomyoma volumes. Fertil Steril 2010;94:371-4.
31.
Sayed GH, Zakherah MS, El-Nashar SA, et al. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose
combined oral contraceptive for fibroid-related menorrhagia. International Journal of Gynecology and Obstetrics 2011;112:126-30.
32.
Socolov D, Blidaru I, Tamba B, et al. Levonorgestrel releasing-intrauterine system for the treatment of menorrhagia and/or frequent irregular
uterine bleeding associated with uterine leiomyoma. Eur J Contracept Reprod Health Care 2011;16:480-7.
33.
Xie ZW, Zhang YN, Wan S, et al. Levonorgestrel-releasing intrauterine device is an efficacious contraceptive for women with leiomyoma. J Int
Med Res 2012;40:1966-72.
34.
Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta
Obstetricia et Gynecologica Scandinavica 1988;67:645-8.
35.
Nilsson L, Rybo G. Treatment of menorrhagia with an antifibrinolytic agent, tranexamix acid Acta Obstetrica et Gynecologica Scandinavica.
1967;46:572-80.
36.
Preston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia.
British Journal of Obstetrics and Gynaecology 1995;102:401-6.
37.
Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: Randomised controlled trial of ethamsylate, mefenamic acid, and
tranexamic acid. British Medical Journal 1996;313:579-82.
38.
Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: A randomized controlled trial. Obstetrics and
Gynecology 2010;116:865-75.
39.
Freeman EW, Lukes A, Van Drie D, et al. A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding.
American Journal of Obstetrics and Gynecology 2011;205.
40.
Chimbira TH, Anderson AB, Naish C, et al. Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of
placebo. British Journal of Obstetrics & Gynaecology 1980;87:1152-8.
41.
Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia.
Australian and New Zealand Journal of Obstetrics and Gynaecology 1991;31:66-70.
42.
Chimbira TH, Cope E, Anderson AB, et al. The effect of danazol on menorrhagia, coagulation mechanisms, haematological indices and body
weight. Br J Obstet Gynaecol 1979;86:46-50.
43.
Chimbira TH, Anderson AB, Cope E, et al. Effect of danazol on serum gonadotrophins and steroid hormone concentrations in women with
menorrhagia. Br J Obstet Gynaecol 1980;87:330-6.
44.
Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. British
Journal of Obstetrics and Gynaecology 1989;96:840-4.
45.
Chamberlain G, Freeman R, Price F, et al. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. Br J
Obstet Gynaecol 1991;98:707-11.
46.
van Eijkeren MA, Christiaens GC, Geuze HJ, et al. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am J Obstet
Gynecol 1992;166:1419-28.